PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
2316.00%
Net income growth above 1.5x VET's 589.13%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-24.50%
Both reduce yoy D&A, with VET at -10.58%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
-345.92%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
No Data
No Data available this quarter, please select a different quarter.
-146.05%
Both reduce yoy usage, with VET at -124.90%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Growth of 100.00% while VET is zero at 0.00%. Bruce Berkowitz would see a difference in minor WC usage that might affect short-term cash flow if large.
4147.62%
Some yoy increase while VET is negative at -530.15%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-48.46%
Both yoy CFO lines are negative, with VET at -4.66%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
38.21%
CapEx growth well above VET's 47.47%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
-84.85%
Negative yoy acquisition while VET stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
-100.00%
Negative yoy purchasing while VET stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
-100.00%
We reduce yoy sales while VET is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
157.62%
Less 'other investing' outflow yoy vs. VET's 24332.33%. David Dodd would see a stronger short-term cash position unless competitor invests more wisely.
155.57%
Investing outflow well above VET's 123.33%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
52.77%
Debt repayment growth of 52.77% while VET is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-50.00%
Negative yoy issuance while VET is 12785.40%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.